Fucoidan dose-dependently alleviated hyperuricemia and modulated gut microbiota in mice

作者：Yanxin Wang, Xiao‐Long Chen, Kai Zhou, Lulu Wang, Yu-Zhen Zhong, Jie Peng, Baosheng Ge, Chi-Tang Ho, Chen-Yang Lu · 发表于：Food & medicine homology. · 年份：2025 · DOI：10.26599/fmh.2026.9420095 · 被引用次数：15 · 研究领域：Gout, Hyperuricemia, Uric Acid、Seaweed-derived Bioactive Compounds、Pharmacological Effects of Natural Compounds

The global incidence of hyperuricemia (HUA) is gradually increasing, and HUA poses a severe threat to human health. Between 25% and 50% of HUA patients are not effectively treated with current clinical medications due to drug contraindications or severe adverse reactions. Therefore, novel safe and effective uric acid-lowering products are needed. Fucoidan is a naturally derived polysaccharide containing sulfate groups exclusively found in brown algae. Although there are reports on the anti-HUA effects of fucoidan, the simultaneous regulation of gut microbiota by anti-HUA still needs to be fully understood. In this study, potassium oxonate (PO) and hypoxanthine-induced HUA model mice were treated with 100, 200 and 400 mg/kg fucoidan (from Laminaria japonica ) for 14 days. The levels associated with HUA were quantified using assay kits to assess fucoidan intervention. 16S rRNA gene sequencing was used to analyze the effects of fucoidan in mice with HUA. The results showed that fucoidan reduced serum uric acid and urea nitrogen levels in a dose-dependent manner, and serum creatinine levels in the 200 and 400 mg/kg fucoidan groups were similar to those in the control group. It decreased the expression of uric acid metabolic protein levels of xanthine oxidase (XOD), adenosine deaminase (ADA), and glucose transporter (GLUT9) and increased ATP binding cassette subfamily G member 2 (ABCG2) protein expression. 16S rRNA gene sequencing revealed that the richness (Chao and Ace indices)...